KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Current Deferred Revenue for 18 consecutive years, with $3.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 88.59% year-over-year to $3.2 million; the TTM value through Mar 2026 reached $3.2 million, down 88.59%, while the annual FY2025 figure was $4.8 million, 91.27% down from the prior year.
  • Current Deferred Revenue hit $3.2 million in Q1 2026 for Alnylam Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $102.8 million in Q4 2023 and bottomed at $2.5 million in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $51.3 million, with a median of $55.5 million recorded in 2024.
  • Year-over-year, Current Deferred Revenue surged 144.04% in 2023 and then plummeted 96.42% in 2025.
  • Alnylam Pharmaceuticals' Current Deferred Revenue stood at $42.1 million in 2022, then soared by 144.04% to $102.8 million in 2023, then plummeted by 46.01% to $55.5 million in 2024, then plummeted by 91.27% to $4.8 million in 2025, then tumbled by 33.68% to $3.2 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $3.2 million, $4.8 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.